Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ABN202
i
Other names:
ABN202
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Abion, Genopharm
Drug class:
EGFR inhibitor, IFN stimulant, TROP2 inhibitor
Related drugs:
‹
cetuximab (317)
osimertinib (240)
erlotinib (229)
afatinib (217)
gefitinib (183)
panitumumab (114)
lapatinib (105)
neratinib (102)
pyrotinib (64)
brigatinib (45)
icotinib (36)
aumolertinib (22)
amivantamab-vmjw (15)
BGB-283 (12)
lazertinib (9)
furmonertinib (8)
mobocertinib (7)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
ASLAN001 (6)
CL-387785 (5)
nimotuzumab (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
BLU-945 (4)
tomuzotuximab (4)
GB263T (4)
JIN-A02 (4)
TAS2940 (4)
EGF816 (4)
BBT-176 (3)
BLU-701 (3)
GC-1118A (3)
ASP8273 (3)
DZD9008 (3)
BCA101 (2)
BI-732 (2)
Bay846 (2)
MCLA-129 (2)
OBX02-011 (2)
olmutinib (2)
necitumumab (2)
QL1203 (2)
S95026 (2)
CLN-081 (2)
14aj (1)
ABP 494 (cetuximab biosimilar) (1)
AFM24 (1)
APL-103 (1)
BLU-451 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
ORIC-114 (1)
befotertinib (1)
TAS3351 (1)
S-222611 (1)
HMPL-813 (1)
ASK120067 (1)
MET306 (1)
SH-1028 (1)
HLX07 (1)
KD019 (1)
human interferon alpha 2b (1)
cetuximab (317)
osimertinib (240)
erlotinib (229)
afatinib (217)
gefitinib (183)
panitumumab (114)
lapatinib (105)
neratinib (102)
pyrotinib (64)
brigatinib (45)
icotinib (36)
aumolertinib (22)
amivantamab-vmjw (15)
BGB-283 (12)
lazertinib (9)
furmonertinib (8)
mobocertinib (7)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
ASLAN001 (6)
CL-387785 (5)
nimotuzumab (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
BLU-945 (4)
tomuzotuximab (4)
GB263T (4)
JIN-A02 (4)
TAS2940 (4)
EGF816 (4)
BBT-176 (3)
BLU-701 (3)
GC-1118A (3)
ASP8273 (3)
DZD9008 (3)
BCA101 (2)
BI-732 (2)
Bay846 (2)
MCLA-129 (2)
OBX02-011 (2)
olmutinib (2)
necitumumab (2)
QL1203 (2)
S95026 (2)
CLN-081 (2)
14aj (1)
ABP 494 (cetuximab biosimilar) (1)
AFM24 (1)
APL-103 (1)
BLU-451 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
ORIC-114 (1)
befotertinib (1)
TAS3351 (1)
S-222611 (1)
HMPL-813 (1)
ASK120067 (1)
MET306 (1)
SH-1028 (1)
HLX07 (1)
KD019 (1)
human interferon alpha 2b (1)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
TROP2 positive
Urothelial Cancer
TROP2 positive
Urothelial Cancer
ABN202
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ABN202
Sensitive
:
D
AACR 2023 - 1wk
ABN202
Sensitive: D – Preclinical
AACR 2023 - 1 week
ABN202
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login